317 related articles for article (PubMed ID: 23344180)
1. Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment.
Betts C; Saleh AF; Arzumanov AA; Hammond SM; Godfrey C; Coursindel T; Gait MJ; Wood MJ
Mol Ther Nucleic Acids; 2012 Aug; 1(8):e38. PubMed ID: 23344180
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
[TBL] [Abstract][Full Text] [Related]
3. In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy.
Wang Q; Yin H; Camelliti P; Betts C; Moulton H; Lee H; Saleh AF; Gait MJ; Wood MJ
J Gene Med; 2010 Apr; 12(4):354-64. PubMed ID: 20235089
[TBL] [Abstract][Full Text] [Related]
4. Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice.
Yin H; Saleh AF; Betts C; Camelliti P; Seow Y; Ashraf S; Arzumanov A; Hammond S; Merritt T; Gait MJ; Wood MJ
Mol Ther; 2011 Jul; 19(7):1295-303. PubMed ID: 21505427
[TBL] [Abstract][Full Text] [Related]
5. A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice.
Yin H; Moulton HM; Betts C; Seow Y; Boutilier J; Iverson PL; Wood MJ
Hum Mol Genet; 2009 Nov; 18(22):4405-14. PubMed ID: 19692354
[TBL] [Abstract][Full Text] [Related]
6. Systemic PPMO-mediated dystrophin expression in the Dup2 mouse model of Duchenne muscular dystrophy.
Gushchina LV; Vetter TA; Frair EC; Bradley AJ; Grounds KM; Lay JW; Huang N; Suhaiba A; Schnell FJ; Hanson G; Simmons TR; Wein N; Flanigan KM
Mol Ther Nucleic Acids; 2022 Dec; 30():479-492. PubMed ID: 36420217
[TBL] [Abstract][Full Text] [Related]
7. Shorter Phosphorodiamidate Morpholino Splice-Switching Oligonucleotides May Increase Exon-Skipping Efficacy in DMD.
Akpulat U; Wang H; Becker K; Contreras A; Partridge TA; Novak JS; Cirak S
Mol Ther Nucleic Acids; 2018 Dec; 13():534-542. PubMed ID: 30396145
[TBL] [Abstract][Full Text] [Related]
8. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
McClorey G; Moulton HM; Iversen PL; Fletcher S; Wilton SD
Gene Ther; 2006 Oct; 13(19):1373-81. PubMed ID: 16724091
[TBL] [Abstract][Full Text] [Related]
9. Exons 45-55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene.
Echigoya Y; Lim KRQ; Melo D; Bao B; Trieu N; Mizobe Y; Maruyama R; Mamchaoui K; Tanihata J; Aoki Y; Takeda S; Mouly V; Duddy W; Yokota T
Mol Ther; 2019 Nov; 27(11):2005-2017. PubMed ID: 31416775
[TBL] [Abstract][Full Text] [Related]
10. Development of DG9 peptide-conjugated single- and multi-exon skipping therapies for the treatment of Duchenne muscular dystrophy.
Lim KRQ; Woo S; Melo D; Huang Y; Dzierlega K; Shah MNA; Aslesh T; Roshmi RR; Echigoya Y; Maruyama R; Moulton HM; Yokota T
Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35193974
[TBL] [Abstract][Full Text] [Related]
11. Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dystrophy.
Malerba A; Kang JK; McClorey G; Saleh AF; Popplewell L; Gait MJ; Wood MJ; Dickson G
Mol Ther Nucleic Acids; 2012 Dec; 1(12):e62. PubMed ID: 23250360
[TBL] [Abstract][Full Text] [Related]
12. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
Heemskerk HA; de Winter CL; de Kimpe SJ; van Kuik-Romeijn P; Heuvelmans N; Platenburg GJ; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108
[TBL] [Abstract][Full Text] [Related]
13. Restoring Dystrophin Expression with Exon 44 and 53 Skipping in the DMD Gene in Immortalized Myotubes.
Echigoya Y; Yokota T
Methods Mol Biol; 2023; 2587():125-139. PubMed ID: 36401027
[TBL] [Abstract][Full Text] [Related]
14. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
[TBL] [Abstract][Full Text] [Related]
15. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.
Maruyama R; Yokota T
Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217
[TBL] [Abstract][Full Text] [Related]
16. A cell-penetrating peptide enhances delivery and efficacy of phosphorodiamidate morpholino oligomers in
Gan L; Wu LCL; Wood JA; Yao M; Treleaven CM; Estrella NL; Wentworth BM; Hanson GJ; Passini MA
Mol Ther Nucleic Acids; 2022 Dec; 30():17-27. PubMed ID: 36189424
[TBL] [Abstract][Full Text] [Related]
17. Enhanced exon skipping and prolonged dystrophin restoration achieved by TfR1-targeted delivery of antisense oligonucleotide using FORCE conjugation in mdx mice.
Desjardins CA; Yao M; Hall J; O'Donnell E; Venkatesan R; Spring S; Wen A; Hsia N; Shen P; Russo R; Lan B; Picariello T; Tang K; Weeden T; Zanotti S; Subramanian R; Ibraghimov-Beskrovnaya O
Nucleic Acids Res; 2022 Nov; 50(20):11401-11414. PubMed ID: 35944903
[TBL] [Abstract][Full Text] [Related]
18. A
Echigoya Y; Trieu N; Duddy W; Moulton HM; Yin H; Partridge TA; Hoffman EP; Kornegay JN; Rohret FA; Rogers CS; Yokota T
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884867
[TBL] [Abstract][Full Text] [Related]
19. Bioinformatic and functional optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic modulation of RNA splicing in muscle.
Popplewell LJ; Graham IR; Malerba A; Dickson G
Methods Mol Biol; 2011; 709():153-78. PubMed ID: 21194027
[TBL] [Abstract][Full Text] [Related]
20. Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice.
Malerba A; Thorogood FC; Dickson G; Graham IR
Hum Gene Ther; 2009 Sep; 20(9):955-65. PubMed ID: 19469709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
